A A Al-Khami1,2,3, M A Ghonim1,4, L Del Valle1,5, S V Ibba1, L Zheng1, K Pyakurel1, S C Okpechi1, J Garay1, D Wyczechowska1, M D Sanchez-Pino1, P C Rodriguez6, A H Boulares1, A C Ochoa1,7. 1. Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA. 2. Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA. 3. Faculty of Science, Tanta University, Tanta, Egypt. 4. Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. 5. Department of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA, USA. 6. University of Augusta Cancer Center, Augusta, GA, USA. 7. Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Abstract
BACKGROUND: Increasing evidence has shown the close link between energy metabolism and the differentiation, function, and longevity of immune cells. Chronic inflammatory conditions such as parasitic infections and cancer trigger a metabolic reprogramming from the preferential use of glucose to the up-regulation of fatty acid oxidation (FAO) in myeloid cells, including macrophages and granulocytic and monocytic myeloid-derived suppressor cells. Asthma is a chronic inflammatory condition where macrophages, eosinophils, and polymorphonuclear cells play an important role in its pathophysiology. OBJECTIVE: We tested whether FAO might play a role in the development of asthma-like traits and whether the inhibition of this metabolic pathway could represent a novel therapeutic approach. METHODS: OVA- and house dust mite (HDM)-induced murine asthma models were used in this study. RESULTS: Key FAO enzymes were significantly increased in the bronchial epithelium and inflammatory immune cells infiltrating the respiratory epithelium of mice exposed to OVA or HDM. Pharmacologic inhibition of FAO significantly decreased allergen-induced airway hyperresponsiveness, decreased the number of inflammatory cells, and reduced the production of cytokines and chemokines associated with asthma. CONCLUSIONS AND CLINICAL RELEVANCE: These novel observations suggest that allergic airway inflammation increases FAO in inflammatory cells to support the production of cytokines, chemokines, and other factors important in the development of asthma. Inhibition of FAO by re-purposing existing drugs approved for the treatment of heart disease may provide a novel therapeutic approach for the treatment of asthma.
BACKGROUND: Increasing evidence has shown the close link between energy metabolism and the differentiation, function, and longevity of immune cells. Chronic inflammatory conditions such as parasitic infections and cancer trigger a metabolic reprogramming from the preferential use of glucose to the up-regulation of fatty acid oxidation (FAO) in myeloid cells, including macrophages and granulocytic and monocytic myeloid-derived suppressor cells. Asthma is a chronic inflammatory condition where macrophages, eosinophils, and polymorphonuclear cells play an important role in its pathophysiology. OBJECTIVE: We tested whether FAO might play a role in the development of asthma-like traits and whether the inhibition of this metabolic pathway could represent a novel therapeutic approach. METHODS: OVA- and house dust mite (HDM)-induced murineasthma models were used in this study. RESULTS: Key FAO enzymes were significantly increased in the bronchial epithelium and inflammatory immune cells infiltrating the respiratory epithelium of mice exposed to OVA or HDM. Pharmacologic inhibition of FAO significantly decreased allergen-induced airway hyperresponsiveness, decreased the number of inflammatory cells, and reduced the production of cytokines and chemokines associated with asthma. CONCLUSIONS AND CLINICAL RELEVANCE: These novel observations suggest that allergic airway inflammation increases FAO in inflammatory cells to support the production of cytokines, chemokines, and other factors important in the development of asthma. Inhibition of FAO by re-purposing existing drugs approved for the treatment of heart disease may provide a novel therapeutic approach for the treatment of asthma.
Authors: E Hamelmann; J Schwarze; K Takeda; A Oshiba; G L Larsen; C G Irvin; E W Gelfand Journal: Am J Respir Crit Care Med Date: 1997-09 Impact factor: 21.405
Authors: Valerie A Gerriets; Rigel J Kishton; Amanda G Nichols; Andrew N Macintyre; Makoto Inoue; Olga Ilkayeva; Peter S Winter; Xiaojing Liu; Bhavana Priyadharshini; Marta E Slawinska; Lea Haeberli; Catherine Huck; Laurence A Turka; Kris C Wood; Laura P Hale; Paul A Smith; Martin A Schneider; Nancie J MacIver; Jason W Locasale; Christopher B Newgard; Mari L Shinohara; Jeffrey C Rathmell Journal: J Clin Invest Date: 2014-12-01 Impact factor: 14.808
Authors: Mohamed A Ghonim; Kusma Pyakurel; Jihang Ju; Paulo C Rodriguez; Matthew R Lammi; Christian Davis; Mohammad Q Abughazleh; Moselhy S Mansy; Amarjit S Naura; A Hamid Boulares Journal: J Allergy Clin Immunol Date: 2014-10-19 Impact factor: 10.793
Authors: Michael D Buck; David O'Sullivan; Ramon I Klein Geltink; Jonathan D Curtis; Chih-Hao Chang; David E Sanin; Jing Qiu; Oliver Kretz; Daniel Braas; Gerritje J W van der Windt; Qiongyu Chen; Stanley Ching-Cheng Huang; Christina M O'Neill; Brian T Edelson; Edward J Pearce; Hiromi Sesaki; Tobias B Huber; Angelika S Rambold; Erika L Pearce Journal: Cell Date: 2016-06-09 Impact factor: 41.582
Authors: Juan R Cubillos-Ruiz; Pedro C Silberman; Melanie R Rutkowski; Sahil Chopra; Alfredo Perales-Puchalt; Minkyung Song; Sheng Zhang; Sarah E Bettigole; Divya Gupta; Kevin Holcomb; Lora H Ellenson; Thomas Caputo; Ann-Hwee Lee; Jose R Conejo-Garcia; Laurie H Glimcher Journal: Cell Date: 2015-06-11 Impact factor: 41.582
Authors: Weiling Xu; Allison J Janocha; Rachel A Leahy; Ryan Klatte; Dave Dudzinski; Lori A Mavrakis; Suzy A A Comhair; Mark E Lauer; Calvin U Cotton; Serpil C Erzurum Journal: Redox Biol Date: 2014-01-16 Impact factor: 11.799
Authors: Stanley Ching-Cheng Huang; Bart Everts; Yulia Ivanova; David O'Sullivan; Marcia Nascimento; Amber M Smith; Wandy Beatty; Latisha Love-Gregory; Wing Y Lam; Christina M O'Neill; Cong Yan; Hong Du; Nada A Abumrad; Joseph F Urban; Maxim N Artyomov; Erika L Pearce; Edward J Pearce Journal: Nat Immunol Date: 2014-08-03 Impact factor: 25.606
Authors: Charalambos Michaeloudes; Pankaj K Bhavsar; Sharon Mumby; Bingling Xu; Christopher Kim Ming Hui; Kian Fan Chung; Ian M Adcock Journal: J Innate Immun Date: 2019-11-29 Impact factor: 7.349
Authors: Mohamed A Ghonim; Salome V Ibba; Abdelmetalab F Tarhuni; Youssef Errami; Hanh H Luu; Matthew J Dean; Ali H El-Bahrawy; Dorota Wyczechowska; Ilyes A Benslimane; Luis Del Valle; Amir A Al-Khami; Augusto C Ochoa; A Hamid Boulares Journal: J Immunother Cancer Date: 2021-01 Impact factor: 13.751
Authors: Priyadarshini Kachroo; Joanne E Sordillo; Sharon M Lutz; Scott T Weiss; Rachel S Kelly; Michael J McGeachie; Ann Chen Wu; Jessica A Lasky-Su Journal: J Pers Med Date: 2021-11-04
Authors: Alberta L Wang; Ronald Panganiban; Weiliang Qiu; Alvin T Kho; Geoffrey Chupp; Deborah A Meyers; Eugene R Bleecker; Scott T Weiss; Quan Lu; Kelan G Tantisira Journal: J Pers Med Date: 2021-03-03